title: [Psychopharmacotherapy during pregnancy : Which antipsychotics, tranquilizers and hypnotics are suitable?].
abstract: BACKGROUND
  When administering psychotropic drugs during pregnancy not only the potential teratogenic effects on the child must be addressed but also the fetotoxic implications for pregnancy and/or the peripartum phase as well as possible neurocognitive developmental disorders must be considered.
  
  
  OBJECTIVE
  Evaluation of the risks and benefits of administering psychotropic drugs during pregnancy or for women who wish to become pregnant.
  
  
  METHODS
  The literature has been reviewed with the purpose of providing information on psychotropic drugs which can safely be administered during pregnancy. The review considers antipsychotics as well as tranquilizers and hypnotics.
  
  
  RESULTS
  Data are available for a multitude of psychotropic drugs that allow a safe estimation on their suitability for use during pregnancy.
  
  
  CONCLUSIONS
  When treating mental illnesses during pregnancy the option of administering drugs must not principally be ruled out. What is required is an individual assessment of benefits and risks. The risk of an untreated mental illness versus the benefit of a suitable treatment, which may include the use of medication and the potential harm to the infant must be evaluated. If certain rules are observed and a suitable drug is selected the risk to the newborn child and/or mother during pregnancy can be minimized. During pregnancy, therapeutic drug monitoring is indicated and increases the safety for use of drugs and preventing harm to both mother and infant.
authors: Sächsisches Krankenhaus Rodewisch, Zentrum für Psychiatrie, Psychotherapie, Psychosomatik und Neurologie, Bahnhofstraße 1, 08228, Rodewisch, Deutschland. niels.bergemann@skhro.sms.sachsen.de.
authors: N
authors: N
authors: Bergemann
authors: Institut für Reproduktionstoxikologie, Krankenhaus St. Elisabeth, Ravensburg, Deutschland.
authors: W E
authors: WE
authors: Paulus
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control*; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination / Q000379:methods; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage*; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D001523:Mental Disorders / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced* / Q000517:prevention & control; D011600:Psychopharmacology; D014149:Tranquilizing Agents / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents
keywords: Drug-induced abnormalities; Neurocognitive disorders; Review; Risk-benefit assessment; Transplacental exposure